Do analysts prefer SYNT or SCPA?

Synthomer presently has a consensus price target of GBX 86.75, suggesting a potential upside of 6.60%. Given Synthomer's stronger consensus rating and higher possible upside, equities research analysts clearly believe Synthomer is more favorable than Scapa Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synthomer 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Scapa Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, SYNT or ESNT?

Essentra has lower revenue, but higher earnings than Synthomer. Synthomer is trading at a lower price-to-earnings ratio than Essentra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Synthomer £1.74B 0.08 -£82.04M -£96.00 N/A Essentra £302M 0.90 £3.50M £0.70 136.71

Is SYNT or ESNT more profitable?

Essentra has a net margin of 0.70% compared to Synthomer's net margin of -9.03%. Essentra's return on equity of 0.79% beat Synthomer's return on equity. Company Net Margins Return on Equity Return on Assets Synthomer -9.03% -16.66% -0.28% Essentra 0.70% 0.79% 1.74%

Which has preferable earnings & valuation, ZTF or SYNT?

Zotefoams has higher earnings, but lower revenue than Synthomer. Synthomer is trading at a lower price-to-earnings ratio than Zotefoams, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zotefoams £158.49M 1.44 £9.80M £44.87 10.34 Synthomer £1.74B 0.08 -£82.04M -£96.00 N/A

Is ZTF or SYNT more profitable?

Zotefoams has a net margin of 14.28% compared to Synthomer's net margin of -9.03%. Zotefoams' return on equity of 18.25% beat Synthomer's return on equity. Company Net Margins Return on Equity Return on Assets Zotefoams 14.28% 18.25% 5.48% Synthomer -9.03% -16.66% -0.28%

Which has stronger valuation & earnings, TET or SYNT?

Treatt has higher earnings, but lower revenue than Synthomer. Synthomer is trading at a lower price-to-earnings ratio than Treatt, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Treatt £128.29M 1.40 £11.22M £7.22 42.24 Synthomer £1.74B 0.08 -£82.04M -£96.00 N/A

Is TET or SYNT more profitable?

Treatt has a net margin of 3.40% compared to Synthomer's net margin of -9.03%. Treatt's return on equity of 3.22% beat Synthomer's return on equity. Company Net Margins Return on Equity Return on Assets Treatt 3.40% 3.22% 6.72% Synthomer -9.03% -16.66% -0.28%

Which has stronger valuation & earnings, SYNT or IOF?

Iofina has lower revenue, but higher earnings than Synthomer. Synthomer is trading at a lower price-to-earnings ratio than Iofina, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Synthomer £1.74B 0.08 -£82.04M -£96.00 N/A Iofina £66.52M 1.66 £4.28M £4.00 14.39

Is SYNT or IOF more profitable?

Iofina has a net margin of 11.84% compared to Synthomer's net margin of -9.03%. Iofina's return on equity of 14.89% beat Synthomer's return on equity. Company Net Margins Return on Equity Return on Assets Synthomer -9.03% -16.66% -0.28% Iofina 11.84% 14.89% 5.18%

Synthomer (SYNT) Competitors

GBX 81.38 -0.62 (-0.76%)

As of 07:43 AM Eastern

Compare

SYNT vs. SCPA, ESNT, ZTF, TET, and IOF

Should you buy Synthomer stock or one of its competitors? MarketBeat compares Synthomer with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Synthomer include Scapa Group (SCPA), Essentra (ESNT), Zotefoams (ZTF), Treatt (TET), and Iofina (IOF). These companies are all part of the "specialty chemicals" industry.

How does Synthomer compare to Scapa Group?

Synthomer (LON:SYNT) and Scapa Group (LON:SCPA) are both small-cap basic materials companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

15.3% of Synthomer shares are owned by institutional investors. 5.0% of Synthomer shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Scapa Group has lower revenue, but higher earnings than Synthomer. Synthomer is trading at a lower price-to-earnings ratio than Scapa Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synthomer	£1.74B	0.08	-£82.04M	-£96.00	N/A
Scapa Group	£281.80M	0.00	N/A	-£29.30	N/A

In the previous week, Synthomer's average media sentiment score of 0.00 equaled Scapa Group'saverage media sentiment score.

Company	Overall Sentiment
Synthomer	Neutral
Scapa Group	Neutral

Scapa Group has a net margin of 0.00% compared to Synthomer's net margin of -9.03%. Scapa Group's return on equity of 0.00% beat Synthomer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synthomer	-9.03%	-16.66%	-0.28%
Scapa Group	N/A	N/A	N/A

Synthomer presently has a consensus price target of GBX 86.75, suggesting a potential upside of 6.60%. Given Synthomer's stronger consensus rating and higher possible upside, equities research analysts clearly believe Synthomer is more favorable than Scapa Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synthomer	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Scapa Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Synthomer beats Scapa Group on 6 of the 10 factors compared between the two stocks.

How does Synthomer compare to Essentra?

Synthomer (LON:SYNT) and Essentra (LON:ESNT) are both small-cap basic materials companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

Essentra has a net margin of 0.70% compared to Synthomer's net margin of -9.03%. Essentra's return on equity of 0.79% beat Synthomer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synthomer	-9.03%	-16.66%	-0.28%
Essentra	0.70%	0.79%	1.74%

Synthomer currently has a consensus target price of GBX 86.75, indicating a potential upside of 6.60%. Essentra has a consensus target price of GBX 150, indicating a potential upside of 56.74%. Given Essentra's stronger consensus rating and higher possible upside, analysts clearly believe Essentra is more favorable than Synthomer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synthomer	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Essentra	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

15.3% of Synthomer shares are held by institutional investors. Comparatively, 69.5% of Essentra shares are held by institutional investors. 5.0% of Synthomer shares are held by insiders. Comparatively, 0.5% of Essentra shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Synthomer has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, Essentra has a beta of 0.829, suggesting that its stock price is 17% less volatile than the broader market.

Essentra has lower revenue, but higher earnings than Synthomer. Synthomer is trading at a lower price-to-earnings ratio than Essentra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synthomer	£1.74B	0.08	-£82.04M	-£96.00	N/A
Essentra	£302M	0.90	£3.50M	£0.70	136.71

In the previous week, Synthomer's average media sentiment score of 0.00 equaled Essentra'saverage media sentiment score.

Company	Overall Sentiment
Synthomer	Neutral
Essentra	Neutral

Summary

Essentra beats Synthomer on 11 of the 14 factors compared between the two stocks.

How does Synthomer compare to Zotefoams?

Zotefoams (LON:ZTF) and Synthomer (LON:SYNT) are both small-cap basic materials companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, risk, institutional ownership, valuation, earnings and analyst recommendations.

Zotefoams has higher earnings, but lower revenue than Synthomer. Synthomer is trading at a lower price-to-earnings ratio than Zotefoams, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zotefoams	£158.49M	1.44	£9.80M	£44.87	10.34
Synthomer	£1.74B	0.08	-£82.04M	-£96.00	N/A

In the previous week, Zotefoams had 1 more articles in the media than Synthomer. MarketBeat recorded 1 mentions for Zotefoams and 0 mentions for Synthomer. Zotefoams' average media sentiment score of 0.76 beat Synthomer's score of 0.00 indicating that Zotefoams is being referred to more favorably in the media.

Company	Overall Sentiment
Zotefoams	Positive
Synthomer	Neutral

Zotefoams presently has a consensus price target of GBX 605, suggesting a potential upside of 30.35%. Synthomer has a consensus price target of GBX 86.75, suggesting a potential upside of 6.60%. Given Zotefoams' stronger consensus rating and higher probable upside, analysts plainly believe Zotefoams is more favorable than Synthomer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zotefoams	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Synthomer	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Zotefoams has a beta of 1.239, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Synthomer has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market.

Zotefoams has a net margin of 14.28% compared to Synthomer's net margin of -9.03%. Zotefoams' return on equity of 18.25% beat Synthomer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zotefoams	14.28%	18.25%	5.48%
Synthomer	-9.03%	-16.66%	-0.28%

29.4% of Zotefoams shares are owned by institutional investors. Comparatively, 15.3% of Synthomer shares are owned by institutional investors. 4.5% of Zotefoams shares are owned by company insiders. Comparatively, 5.0% of Synthomer shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Zotefoams beats Synthomer on 14 of the 16 factors compared between the two stocks.

How does Synthomer compare to Treatt?

Treatt (LON:TET) and Synthomer (LON:SYNT) are both small-cap basic materials companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations.

Treatt has a net margin of 3.40% compared to Synthomer's net margin of -9.03%. Treatt's return on equity of 3.22% beat Synthomer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Treatt	3.40%	3.22%	6.72%
Synthomer	-9.03%	-16.66%	-0.28%

Treatt has a beta of 0.907, meaning that its share price is 9% less volatile than the broader market. Comparatively, Synthomer has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market.

Treatt currently has a consensus target price of GBX 248.33, suggesting a potential downside of 18.58%. Synthomer has a consensus target price of GBX 86.75, suggesting a potential upside of 6.60%. Given Synthomer's higher possible upside, analysts clearly believe Synthomer is more favorable than Treatt.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Treatt	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Synthomer	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

17.5% of Treatt shares are owned by institutional investors. Comparatively, 15.3% of Synthomer shares are owned by institutional investors. 4.1% of Treatt shares are owned by insiders. Comparatively, 5.0% of Synthomer shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Treatt has higher earnings, but lower revenue than Synthomer. Synthomer is trading at a lower price-to-earnings ratio than Treatt, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Treatt	£128.29M	1.40	£11.22M	£7.22	42.24
Synthomer	£1.74B	0.08	-£82.04M	-£96.00	N/A

In the previous week, Treatt's average media sentiment score of 0.00 equaled Synthomer'saverage media sentiment score.

Company	Overall Sentiment
Treatt	Neutral
Synthomer	Neutral

Summary

Treatt beats Synthomer on 10 of the 14 factors compared between the two stocks.

How does Synthomer compare to Iofina?

Synthomer (LON:SYNT) and Iofina (LON:IOF) are both small-cap basic materials companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

Synthomer currently has a consensus target price of GBX 86.75, suggesting a potential upside of 6.60%. Iofina has a consensus target price of GBX 65, suggesting a potential upside of 12.95%. Given Iofina's stronger consensus rating and higher possible upside, analysts clearly believe Iofina is more favorable than Synthomer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synthomer	0 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Iofina	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Synthomer has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, Iofina has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market.

Iofina has a net margin of 11.84% compared to Synthomer's net margin of -9.03%. Iofina's return on equity of 14.89% beat Synthomer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synthomer	-9.03%	-16.66%	-0.28%
Iofina	11.84%	14.89%	5.18%

15.3% of Synthomer shares are held by institutional investors. Comparatively, 1.5% of Iofina shares are held by institutional investors. 5.0% of Synthomer shares are held by company insiders. Comparatively, 13.4% of Iofina shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Iofina had 1 more articles in the media than Synthomer. MarketBeat recorded 1 mentions for Iofina and 0 mentions for Synthomer. Iofina's average media sentiment score of 0.67 beat Synthomer's score of 0.00 indicating that Iofina is being referred to more favorably in the news media.

Company	Overall Sentiment
Synthomer	Neutral
Iofina	Positive

Iofina has lower revenue, but higher earnings than Synthomer. Synthomer is trading at a lower price-to-earnings ratio than Iofina, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synthomer	£1.74B	0.08	-£82.04M	-£96.00	N/A
Iofina	£66.52M	1.66	£4.28M	£4.00	14.39

Summary

Iofina beats Synthomer on 13 of the 16 factors compared between the two stocks.

Get Synthomer News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYNT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SYNT vs. The Competition

Export

Metric	Synthomer	Specialty Chemicals Industry	Materials Sector	LON Exchange
Market Cap	£133.41M	£8.44B	£4.55B	£2.83B
Dividend Yield	28.47%	3.32%	5.02%	6.15%
P/E Ratio	-0.85	16.31	21.09	368.41
Price / Sales	0.08	129.16	5,716.31	84,450.12
Price / Cash	2.28	19.63	24.09	27.89
Price / Book	0.12	3.55	8.58	7.40
Net Income	-£82.04M	£213.62M	£156.22M	£5.89B
7 Day Performance	-0.15%	1.23%	1.34%	0.94%
1 Month Performance	1.22%	1.99%	-1.57%	0.76%
1 Year Performance	-15.23%	24.51%	35.54%	68.76%

Synthomer Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SYNT Synthomer	1.1855 of 5 stars	GBX 81.38 -0.8%	GBX 86.75 +6.6%	-14.6%	£133.41M	£1.74B	N/A	4,200	Gap Up
SCPA Scapa Group	N/A	N/A	N/A	N/A	£402.98M	£281.80M	N/A	1,461
ESNT Essentra	1.9316 of 5 stars	GBX 83.82 +0.0%	GBX 150 +79.0%	-10.2%	£237.59M	£302M	119.74	350	Positive News
ZTF Zotefoams	4.1791 of 5 stars	GBX 420 -2.6%	GBX 605 +44.0%	+50.0%	£206.56M	£158.49M	9.36	549	Positive News
TET Treatt	N/A	GBX 305 flat	GBX 248.33 -18.6%	N/A	£180.06M	£128.29M	42.24	350

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:SYNT) was last updated on 7/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Synthomer (SYNT) Competitors

SYNT vs. SCPA, ESNT, ZTF, TET, and IOF

How does Synthomer compare to Scapa Group?

Summary

How does Synthomer compare to Essentra?

Summary

How does Synthomer compare to Zotefoams?

Summary

How does Synthomer compare to Treatt?

Summary

How does Synthomer compare to Iofina?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYNT vs. The Competition

Synthomer Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Synthomer (SYNT) Competitors

SYNT vs. SCPA, ESNT, ZTF, TET, and IOF

How does Synthomer compare to Scapa Group?

Do insiders & institutionals hold more shares of SYNT or SCPA?

Which has preferable valuation & earnings, SYNT or SCPA?

Does the media prefer SYNT or SCPA?

Is SYNT or SCPA more profitable?

Do analysts prefer SYNT or SCPA?

Summary

How does Synthomer compare to Essentra?

Is SYNT or ESNT more profitable?

Do analysts prefer SYNT or ESNT?

Do insiders and institutionals have more ownership in SYNT or ESNT?

Which has more risk and volatility, SYNT or ESNT?

Which has better valuation & earnings, SYNT or ESNT?

Does the media prefer SYNT or ESNT?

Summary

How does Synthomer compare to Zotefoams?

Which has preferable earnings & valuation, ZTF or SYNT?

Does the media favor ZTF or SYNT?

Do analysts recommend ZTF or SYNT?

Which has more volatility & risk, ZTF or SYNT?

Is ZTF or SYNT more profitable?

Do institutionals and insiders hold more shares of ZTF or SYNT?

Summary

How does Synthomer compare to Treatt?

Is TET or SYNT more profitable?

Which has more volatility and risk, TET or SYNT?

Do analysts prefer TET or SYNT?

Do insiders and institutionals hold more shares of TET or SYNT?

Which has stronger valuation & earnings, TET or SYNT?

Does the media favor TET or SYNT?

Summary

How does Synthomer compare to Iofina?

Do analysts prefer SYNT or IOF?

Which has more volatility & risk, SYNT or IOF?

Is SYNT or IOF more profitable?

Do insiders & institutionals hold more shares of SYNT or IOF?

Does the media prefer SYNT or IOF?

Which has stronger valuation & earnings, SYNT or IOF?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SYNT vs. The Competition

Synthomer Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools